The efficacy of venlafaxine XR (Efexor XR) versus SSRIS [selective serotonin reuptake inhibitors] and conventional antidepressants in depressed patients switched from prior antidepressants in psychiatric outpatient care settings in China.

Trial Profile

The efficacy of venlafaxine XR (Efexor XR) versus SSRIS [selective serotonin reuptake inhibitors] and conventional antidepressants in depressed patients switched from prior antidepressants in psychiatric outpatient care settings in China.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Venlafaxine (Primary) ; Antidepressants; Serotonin uptake inhibitors
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Wyeth
  • Most Recent Events

    • 02 Mar 2012 Company (Pfizer) added as trial sponsor as reported by ClinicalTrials.gov.
    • 04 May 2010 Actual number of patients added as 1151 as reported by ClinicalTrials.gov.
    • 28 Jan 2009 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top